EQS-News: CLINUVEL Update: CEO Comeback & US Expansion Drive: Vitiligo approval and M&A as growth catalysts in North America

Frankfurt am Main, June 23, 2025 – CLINUVEL Pharmaceuticals Ltd. (ASX: CUV; WKN: AOJEGY) is setting key strategic signals for its next growth phase: Following a full recovery, CEO Dr. Philippe Wolgen has returned to lead the company’s operations and is now driving forward expansion into the North American market. The targeted approval of SCENESSE® for the treatment of vitiligo in the United States and Canada is expected to mark a potential turning point in CLINUVEL’s business model.At the same time, CLINUVEL is accelerating its presence in the U.S. through targeted M&A activities, aiming to rapidly achieve critical scale in the world’s most important pharmaceutical market. Currently, 104 of 120 treatment centers for EPP patients are active – and are expected to be ready for future use in treating vitiligo patients.“Dr. Wolgen’s return marks a pivotal moment for CLINUVEL. His strategic vision and the company’s financial strength create the foundation for sustainable growth and a new market position in North America,” said Thomas Schiessle, Analyst at Parmantier & Cie. Research.With a strong balance sheet, high liquidity, and a defensive core business focused on EPP treatment, CLINUVEL is well-positioned. Analysts at Parmantier & Cie. confirm their target price of AUD 22.00 and reiterate a Buy recommendation, with upside potential of +126% relative to the current share price.Further positive impulses could arise from European regulators – particularly through the planned extension of SCENESSE® approval to adolescent EPP patients and unified treatment guidance from the EMA.Full research report available at:Bloomberg ; FactSet ; LSEGOnline: www.parmantiercie.com/researchAbout PARMANTIER & CIE. GmbHPARMANTIER & CIE. is a modern merchant bank based in Frankfurt am Main. The firm advises companies on all aspects of financing – equity, debt, and hybrid instruments – and also invests its own capital in listed and private companies. PARMANTIER & CIE. stands for integrity, foresight, and tailored financing solutions with entrepreneurial commitment.Contact for further inquiries:Parmantier & Cie. ResearchHungener Straße 660389 Frankfurt am MainE-mail: info@parmantiercie.com